ViferaXS Secures €12 Million to Fund Phase II Trial in Chronic Lymphocytic Leukemia and Expand Oncology Pipeline
ViferaXS, a clinical-stage biotechnology company based in Tübingen, Germany, has raised up to €12 million through its Series A financing round. The funding includes grant support from SPRIND (the German Federal Agency for Breakthrough Innovation) and Huma, alongside private investors. These funds will be used primarily to advance the Phase II trial of CLLTAXS01 in chronic lymphocytic leukemia (CLL), as well as ongoing Phase I trials in acute myeloid leukemia (AML) and fibrolamellar carcinoma (FLC). The financing also supports team expansion, preclinical development for additional indications, and data sharing from the AML and FLC programs soon. ViferaXS is developing a proprietary T Cell Activator technology aimed at activating cytotoxic T cells against tumor antigens. CEO Sezai Taskin expressed optimism about early clinical results of CLLTAXS01 in moving forward with randomized trials, while SPRIND's Patrick Rose highlighted the company’s potential to transform cancer care through innovative immunotherapy approaches. Huma is also contributing its AI-powered platform for clinical trial execution and data integration. The collaboration aims to accelerate ViferaXS' mission of bringing new therapies to patients.
Topics: biotech cancer immunotherapy clinical trials financing